Encompass Health Corporation

Encompass Health Corporation (EHC) Market Cap

Encompass Health Corporation has a market capitalization of $10.32B.

Price: $104.01

4.17 (4.18%)

Market Cap: 10.32B

NYSE · time unavailable

CEO: Mark J. Tarr

Sector: Healthcare

Industry: Medical - Care Facilities

IPO Date: 1986-09-24

Website: https://www.encompasshealth.com

Encompass Health Corporation (EHC) - Company Information

Market Cap: 10.32B|Sector: Healthcare

Company Profile

Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations. The Home Health and Hospice segment provides home health and hospice services primarily in the Southeast and Texas. Its home health services include a range of Medicare-certified home nursing services to adult patients in need of care comprising skilled nursing, medical social work, and home health aide services, as well as physical, occupational, speech therapy, and others. This segment's hospice services comprise in-home services to terminally ill patients and their families. As of June 1, 2022, it operated 149 hospitals, 252 home health locations, and 99 hospice locations in 42 states and Puerto Rico. The company was formerly known as HealthSouth Corporation and changed its name to Encompass Health Corporation in January 2018. Encompass Health Corporation was founded in 1983 and is based in Birmingham, Alabama.

Analyst Sentiment

92%
Strong Buy

From 13 Active Polls

1Y Forecast: $146.00

▲ +40.4% Potential Upside

Consensus Target Metrics

Low Bound

$140

Median

$146

High Bound

$152

Average

$146

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$146.00
▲ +40.37% Upside
Low Target
$140.00
35% Risk
Median Target
$146.00
40% Mid
High Target
$152.00
46% Max
Consensus
Buy
21 / 26 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)10,3189,59610,63512,76612,33710,1799,2359,6548,527
Enterprise Value ($M)12,94412,22213,24615,37814,88512,78611,86312,25511,291
Price to Earnings Ratio (P/E)16.9412.3318.2025.2321.7016.8019.1022.3118.68
Price/Earnings-to-Growth Ratio (PEG)4.544.0118.57137.344.684.785.83
Price to Sales Ratio (P/S)1.706.056.898.648.466.996.577.156.55
Price to Book Ratio (P/B)4.093.814.365.385.414.714.474.934.64
Price to Free Cash Flow Ratio (P/FCF)22.2263.6791.13152.52108.8881.10115.2980.25140.95
Enterprise Value to Sales (EV/Sales)7.708.5810.4110.218.788.449.078.68
Enterprise Value to EBITDA (EV/EBITDA)8.9731.4335.3946.1742.8836.5737.9841.2538.51
Debt to Equity Ratio1.821.111.111.121.181.251.311.431.60

EHC Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$104.01
Intrinsic Value$17.61
Market Alignment
Overvalued by 83.1%relative to calculated intrinsic value
9.00%
Exp: 10%10%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2035)

Terminal FCF Base$0.29B
Perpetuity TV Value$5.48B
Discounted TV (PV)$2.31B
TV Weighting %63.4%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 ENCOMPASS HEALTH CORP (EHC) — Investment Overview

🧩 Business Model Overview

Encompass Health operates a network of inpatient rehabilitation hospitals (IRFs) and outpatient rehabilitation services. The value chain begins with acute-care hospitals and physicians referring patients who need intensive, goal-oriented rehabilitation after major events such as stroke, major orthopedic surgery, or other complex medical conditions. Encompass then delivers therapy services through multidisciplinary clinical teams, coordinated around functional outcome goals and payer-specific authorization requirements.

A key element of the model is operational continuity: many patients move from inpatient rehabilitation to outpatient therapy within the same operator network, supporting care coordination, referral relationships, and ongoing patient flow.

💰 Revenue Streams & Monetisation Model

Revenue is predominantly driven by inpatient rehabilitation admissions and associated Medicare/managed-care reimbursement, supplemented by outpatient therapy services billed per visit/episode and through contractual payer arrangements. Monetisation is strongly linked to (1) patient volume and mix, (2) average length of stay and therapy intensity, and (3) case-level reimbursement outcomes under Medicare’s IRF payment framework and commercial payer contracts.

Margin drivers typically include occupancy and throughput discipline (care capacity utilization), staffing productivity (therapy minutes per staff hour), contract/payer reimbursement rates, and the ability to manage variable costs such as labor and supplies. Outpatient services can contribute to smoother volume patterns and improve utilization across therapist and administrative infrastructure.

🧠 Competitive Advantages & Market Positioning

Moat: Regulatory + Operational Barriers with Local Switching Costs. While healthcare delivery is operationally competitive, taking share in IRFs is constrained by (a) regulatory and reimbursement complexity and (b) the difficulty of replicating referral trust and therapy team performance across a new site.

  • High Barriers to Entry (Regulatory/Certification): IRF operations depend on Medicare compliance, documentation standards, and facility-level requirements. Competitors face friction in scaling compliant capacity quickly, especially under stringent medical-necessity and coding expectations.
  • Referral Relationship Switching Costs: Acute-care discharge planners and physicians build patient-flow expectations around established outcomes, therapist capacity, and administrative reliability. Once a system is embedded into referral workflows, switching can be operationally costly and riskier for referring providers.
  • Cost Advantages from Operating Scale: Standardized clinical protocols, centralized administrative functions, and established labor scheduling can improve therapy productivity and reduce per-unit overhead compared with lower-scale operators.
  • Integrated Ecosystem: The ability to transition patients from inpatient rehabilitation to outpatient therapy supports continuity of care, strengthens patient retention, and reduces the marginal cost of maintaining referral demand.

Competitive benchmarking: Encompass Health’s primary competitive set spans both inpatient and outpatient rehab services. Key competitors include:

  • Select Medical (inpatient rehab and outpatient therapy platforms): competes for IRF admissions and outpatient visits with a similar national scale approach.
  • Vibra Healthcare / Kindred-legacy post-acute platforms (institutional post-acute alternatives): compete for medically complex discharges that can otherwise be directed toward IRF-level rehabilitation.
  • ATI Physical Therapy and other large outpatient therapy operators: compete for outpatient follow-on therapy volume after discharge.

Encompass’s positioning is most distinct in its focused operating footprint and execution discipline in IRFs, supported by an outpatient network that reinforces referral stickiness and patient continuity.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is supported by structural demand for rehabilitation services and by capacity/market share expansion where reimbursement and referral ecosystems support utilization.

  • Demographic demand for post-acute rehabilitation: Aging populations and the prevalence of stroke, joint replacement, and chronic disease management increase the addressable population needing intensive rehab.
  • Share shift within the discharge pathway: Acute-care systems continue to refine discharge destinations to match clinical needs and resource constraints, supporting sustained utilization for properly positioned IRFs.
  • Expansion of compliant, high-quality capacity: New facility builds, strategic acquisitions, and therapy network extensions can add beds and outpatient sites, especially in markets where referral demand is under-served.
  • Improving payer mix and contract participation: Managed care arrangements and value-based pilots can support growth when operational outcomes and documentation capabilities translate into favorable reimbursement terms.
  • Operational leverage as volume scales: Once staffing and facility workflows are established, incremental admissions can improve utilization and spread fixed costs across more patient-days.

⚠ Risk Factors to Monitor

  • Reimbursement and policy risk: Changes to Medicare IRF payment mechanics, wage index impacts, documentation requirements, and utilization controls can pressure unit economics.
  • Regulatory/compliance and coding risk: Medical-necessity and documentation scrutiny can affect case-level reimbursement and create administrative and legal exposure.
  • Labor cost and staffing availability: Rehabilitation is labor-intensive; wage inflation, therapist shortages, and productivity variation can compress margins.
  • Occupancy and referral demand volatility: Referral patterns can shift with discharge practices, competing facility capacity, or payer utilization management.
  • Capital intensity of growth: Building and acquiring inpatient capacity requires disciplined capital allocation and integration execution to sustain returns.

📊 Valuation & Market View

The market typically values rehab providers using cash-flow-oriented metrics (such as EV/EBITDA and enterprise value versus operating income), with sensitivity to utilization/occupancy, labor costs, reimbursement stability, and regulatory outcomes.

Key valuation drivers include:

  • Sustainable margin level supported by throughput and staffing productivity
  • Visibility of reimbursement economics under Medicare and commercial contracts
  • Quality of growth (returns on incremental admissions and the integration success of new sites)
  • Operating leverage as patient-days scale

🔍 Investment Takeaway

Encompass Health offers an investable long-term profile driven by structurally growing demand for post-acute rehabilitation and by durable operational advantages rooted in regulatory complexity, referral stickiness, and an integrated inpatient-to-outpatient ecosystem. The core thesis rests on the company’s ability to maintain compliant clinical execution, manage labor productivity, and expand capacity in markets where referral networks and reimbursement economics support sustained utilization and margin resilience.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for EHC.

zacks.com2026-06-05

Here's Why Encompass Health (EHC) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com2026-06-03

Why Encompass Health (EHC) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com2026-06-01

Encompass Health to Expand WV Footprint With 36-Bed Bridgeport Unit

EHC is expanding its rehabilitation network with a new 36-bed hospital in West Virginia.

prnewswire.com2026-05-29

Encompass Health to build 36-bed inpatient rehabilitation hospital in Bridgeport, West Virginia

BIRMINGHAM, Ala. and BRIDGEPORT, W.Va.

zacks.com2026-05-28

Encompass Health (EHC) is a Top-Ranked Momentum Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com2026-05-19

Can Encompass Health's Expansion Strategy Make It a Hold for Now?

EHC expands rehab capacity with new hospitals and bed additions, but rising labor costs and debt levels may keep the stock a Hold for now.

zacks.com2026-05-19

Why Encompass Health (EHC) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

prnewswire.com2026-05-14

Encompass Health issues notice for partial redemption of its 4.500% senior notes due 2028

BIRMINGHAM, Ala., May 14, 2026 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today issued notice for redemption of $400 million of the outstanding principal balance of its 4.500% senior notes due 2028 (the "2028 Notes").

prnewswire.com2026-05-14

Encompass Health announces pricing of $500 million of senior notes due 2034 in a private offering

BIRMINGHAM, Ala., May 14, 2026 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced the pricing of a private offering of $500 million in aggregate principal amount of 5.875% senior notes due 2034 (the "Notes") at a price of 100% of the principal amount thereof.

zacks.com2026-05-14

Here's Why Encompass Health (EHC) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

prnewswire.com2026-05-14

Encompass Health announces private offering of senior notes

BIRMINGHAM, Ala., May 14, 2026 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced it has commenced a private offering of $500 million in aggregate principal amount of senior notes maturing in 2034 (the "Notes"), subject to market and other conditions.

seekingalpha.com2026-05-12

Encompass Health Corporation (EHC) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Encompass Health Corporation (EHC) Presents at Bank of America Global Healthcare Conference 2026 Transcript

zacks.com2026-05-12

Encompass Health to Expand Idaho Presence With New 50-Bed Facility

EHC plans a new 50-bed inpatient rehab hospital in Post Falls, expanding its footprint in an underserved market with an expected 2028 opening.

prnewswire.com2026-05-11

Encompass Health announces plans to build a 50-bed inpatient rehabilitation hospital in Post Falls, Idaho

BIRMINGHAM, Ala., and POST FALLS, Idaho, May 11, 2026 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced plans to build a freestanding, 50–bed inpatient rehabilitation hospital in Post Falls, Idaho.

businesswire.com2026-05-08

Encompass Health Acquires 7 Acres in Haslet for New Inpatient Rehabilitation Hospital

HASLET, Texas--(BUSINESS WIRE)--Davidson Bogel Real Estate (DB2RE) is pleased to announce the sale of approximately 7 acres of land located at the southwest corner of Haslet Parkway and Harmon Road in Haslet, Texas. Collins Meier, Ryan Turner, David Davidson, Jr., and Edward Bogel represented the seller in the transaction. The buyer, Encompass Health, partnered closely with the land owner and master developer, Terra Manna, to bring the project to fruition. JLL represented the buyer in the trans.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"EHC (2026-03-31, Q1) reported Revenue of $1.59B and Net Income of $194.5M (EPS $1.80). YoY, revenue rose +9.0% ($1.59B vs. $1.46B) and net income increased +28.4% ($194.5M vs. $151.5M). QoQ (vs. 2025-12-31), revenue grew +2.7%, while net income climbed +33.1% ($194.5M vs. $146.1M). Profitability improved across the quarter: net margin expanded to 12.3% from 9.5% in Q4 and 10.4% in Q1 last year, indicating meaningful operating improvement and better earnings conversion. Cash flow quality was volatile. Operating cash flow was $21.2M in Q1, down sharply from $346.0M in Q4, and free cash flow was negative ($-141.2M) due to heavier capex/investing outflows in the quarter. Balance sheet strength looks mixed: total assets increased to $7.31B, but leverage and debt are not the primary issue for a non-bank—equity jumped to $3.31B (from $3.28B and $2.38B earlier in the year history), while cash ended at $110.5M. Shareholder returns appear modest: the stock is up only +3.29% over 1Y and offers a very small dividend yield (~0.21%); there is no strong momentum tailwind."

Revenue Growth

Positive

QoQ revenue +2.7% (Q1: $1.59B vs Q4: $1.54B). YoY revenue +9.0% (vs Q1 2025: $1.46B), showing a steady upward trend.

Profitability

Good

Net income YoY +28.4% and QoQ +33.1%. Net margin expanded to 12.3% (from 9.5% in Q4 and 10.4% in Q1 last year).

Cash Flow Quality

Caution

Operating cash flow fell to $21.2M (from $346.0M in Q4). Free cash flow was negative at $-141.2M, indicating weaker near-term cash generation despite higher earnings.

Leverage & Balance Sheet

Neutral

Total assets rose to $7.31B. Equity is higher at $3.31B versus prior periods shown, and liquidity improved with cash at $110.5M, but debt remains present.

Shareholder Returns

Fair

Dividend yield is low (~0.21%) and 1Y price change is +3.29%, with no >20% momentum boost. Buybacks occurred, but total-return momentum is moderate.

Analyst Sentiment & Valuation

Positive

Consensus target is $153 versus price $106.39 (~+44% upside). This supports the valuation component despite recent cash-flow softness.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Q1 2026 showed strong top-line and profitability momentum for EHC: revenue grew 9% to $1.59B and adjusted EBITDA rose 11.2% to $348.8M. Quality improved across discharge metrics (community +50 bps to 84.5%, acute +30 bps to 8.6%, SNF +20 bps to 6.2%), alongside major labor wins—annualized RN turnover fell to 17.8% (lowest since at least 2012) and premium labor spend declined 9.4%. Despite the operational strength, management flagged volume headwinds: unit closures reduced discharges by ~85 bps (EBITDA-neutral), and occupancy is now the limiting factor in a subset of hospitals (35% >90% occupancy; ~95% average). MA trends also remain a drag, though conversion sequentially improved and admit-and-appeal began end of February in 9 hospitals. Guidance was raised for 2026, and CMS’s 2027 IRF proposed rule implied a 2.4% Medicare pricing increase effective October 1, 2026, with the final rule expected in late July/early August.

AI IconGrowth Catalysts

  • Discharge growth lifted by higher net revenue per discharge (+3.7% net revenue per discharge) and 1.6% same-store discharge growth
  • Quality metric improvement: discharge community +50 bps to 84.5%, discharge acute +30 bps to 8.6%, discharge to SNF +20 bps to 6.2%
  • Capacity build-out: opened a 49-bed hospital in Irma, South Carolina (11th hospital in the state) and added 44 beds to existing hospitals

Business Development

  • Irma, South Carolina: opened new 49-bed hospital (11th hospital in the state)
  • Evansville, Indiana: closure of a previously announced 18-bed hospital-in-hospital unit hosted within an acute care hospital JV partner; closure expected early 2027 with additional 40 beds to the freestanding hospital operational late 2026
  • Pipeline: announced new hospital projects beyond 2026 totaling 11 hospitals / 520 beds; management expects additional announcements including small-format hospitals

AI IconFinancial Highlights

  • Revenue up 9% to $1.59B; adjusted EBITDA up 11.2% to $348.8M
  • Adjusted EPS guidance raised to $5.89–$6.11 for 2026 (raised based on Q1 results); adjusted EBITDA guidance raised to $1.35B–$1.38B; net operating revenue guidance raised to $6.375B–$6.470B
  • Bad debt expense increased 20 bps to 2.2%, driven by write-offs of 2013 claims tied to a legacy audit appeal
  • Discharge growth headwind from unit closures: ~85 bps impact on total and same-store discharge growth; management stated closures were essentially breakeven in adjusted EBITDA (discharges only impacted)
  • SWB per FTE increased 3.7%, attributed to increased state-directed payment revenue (including out-of-period items) plus favorable Medicare SSI YoY impact; management noted favorable closure-related mix effect
  • RN turnover improved materially: Q1 annualized RN turnover 17.8% vs 20.2% FY25; therapist turnover 6.4% vs 7.8% FY25; annualized decline contributed to 9.4% decline in premium labor spend

AI IconCapital Funding

  • Share repurchase: ~708,000 shares repurchased for $71.6M during Q1
  • Dividends: paid $0.19/share cash dividend and declared another $0.19/share paid in April
  • Leverage/liquidity: net leverage 1.9x at quarter end; funded debt ~$2.575B
  • Free cash flow: Q1 adjusted free cash flow $194M; management guidance midpoint free cash flow estimate ~$818M and cited ~$858M cash available for investment after including ~$40M additional cash from legal-related proceeds

AI IconStrategy & Ops

  • Clinical staffing/retention: centralized talent acquisition and nurse clinical ladders—~35% of nursing staff on ladders (up ~300 bps vs prior quarter); turnover for ladder nurses ~2% vs 20.7% non-laddered
  • Operating model for growth/constraints: occupancy becoming a constraint in select markets; management increased internal occupancy threshold for bed expansion to 70%–75% from prior 80%–85% due to longer permitting/regulatory timelines
  • Hospital format evolution: small-format hospital concept to enable hub-and-spoke strategy; remote locations under same Medicare provider number as an in-market hospital sharing administrative services
  • Capacity plan: over balance of 2026, open 7 more hospitals totaling 340 beds; add 100–150 beds to existing hospitals
  • Capex outlook: capex as % of revenue expected to increase modestly, peak at ~15% before receding toward 10%–12% long-run

AI IconMarket Outlook

  • Regulatory timing: TEAM begins January 1; RCD expansion into Texas effective March 1; RCD expansion into California begins today (Q1 2026 call date context)
  • CMS 2027 IRF proposed rule (released April 2): net market basket update 2.4%, estimated to translate to a 2.4% pricing increase for Medicare patients beginning October 1, 2026; final rule expected late July or early August
  • Management expects Q1 closures’ discharge growth impact to diminish through consolidation and anniversarying closure dates
  • State-directed payment taxes/provider tax: management expects net provider tax EBITDA impact for full year 2026 to be relatively flat YoY vs last year ($21M), with Q1 increase attributed to timing/out-of-period items (out-of-period EBITDA impact about $4.2M in Q1)

AI IconRisks & Headwinds

  • Occupancy constraint: Q1 average occupancy 78.7% (flat vs Q1 2025 record high, up from Q1 2024 and Q1 2023); ~35% of hospitals had occupancy >90% with cohort average occupancy ~95%, constraining discharge growth until bed additions occur
  • MA trends: management described industry MA penetration peaking around ~52% and receding; 20 states saw MA penetration decline YoY (48 of 154 home counties, 31%, declined); management cited continued MA-related volume drag despite improving sequential MA conversion
  • Seasonality: Q1 ‘26 had relatively light flu/respiratory season vs prior year, potentially moderating debility-related mix (debility ~11% of patient mix; +70 bps total quarter, but -1.5% same-store)
  • One-time financial headwind: bad debt +20 bps to 2.2% due to write-offs tied to legacy audit appeal claims

Q&A: Analyst Interest

  • Discharge growth impact from unit closures: Management quantified closures as ~85 bps headwind to both total and same-store discharge growth, with no adjusted EBITDA impact because closures were essentially breakeven. They also said the impact should diminish during the year as volume is consolidated and closure anniversary timing is reached.
  • Drivers of exceptionally low nursing turnover: Management attributed improvements to centralized talent acquisition bringing in net hires, plus clinical ladder penetration rising to ~35% of nurses (+300 bps). They stated ladder nurses had ~2% turnover vs 20.7% for non-ladder nurses, reinforcing retention and labor-cost reduction.
  • Same-store volume moderation: Management cited four Q1 factors—unit closures (~85 bps), occupancy constraints (35% of hospitals >90% occupancy, ~95% avg), light flu/respiratory severity (debility proxy), and ongoing MA pressure. They highlighted admit-and-appeal piloting in 9 hospitals starting end of February as early evidence of improved authorization approvals.

Sentiment: MIXED

Note: This summary was synthesized by AI from the EHC Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for EHC.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (EHC)

© 2026 Stock Market Info — Encompass Health Corporation (EHC) Financial Profile